Stufano Angela, Capone Giovanni, Pesetti Barbara, Polimeno Lorenzo, Kanduc Darja
Department of Biochemistry and Molecular Biology; University of Bari; Bari, Italy.
Self Nonself. 2010 Apr;1(2):154-162. doi: 10.4161/self.1.2.11391. Epub 2010 Feb 3.
Our previous research and a comprehensive meta-analysis of data from the literature on epitope mapping has revealed that the B cell epitope repertoire is allocated to rare peptide motifs, i.e., antigenic peptide sequences endowed with a low level of similarity to the host proteome. From a clinical point of view, low-similarity peptides able to evoke an immune response appear to be of special interest for the rational design of vaccines for poorly treatable diseases such as hepatitis-C virus (HCV) infection. Indeed, low similarity peptides would guarantee the highest specificity and lowest cross-reactivity, i.e., effectiveness without adverse side-effects. In this study, aimed at gaining further information for the development of effective anti-HCV peptide-based vaccines, the HCV epitopes recognized by human antibodies and currently catalogued in the Immune Epitope Data Base (IEDB) were examined for pentamer sequence similarities to the human proteome. We report that the analyzed HCV determinants are characterized by the presence of fragment absent from (or scarcely represented in) human proteins. These data confirm the low-similarity hypothesis, according to which a low-similarity to the host proteome defines the nonself character of microbial antigens and modulates peptide immunogenicity. Moreover, this study indicates a concrete and safe immunotherapeutic approach which might be used in a universal anti-HCV vaccine.
我们之前的研究以及对来自表位作图文献数据的综合荟萃分析表明,B细胞表位库被分配到罕见的肽基序,即与宿主蛋白质组具有低相似性水平的抗原肽序列。从临床角度来看,能够引发免疫反应的低相似性肽对于合理设计针对诸如丙型肝炎病毒(HCV)感染等难以治疗疾病的疫苗似乎具有特殊意义。实际上,低相似性肽将保证最高的特异性和最低的交叉反应性,即有效且无不良副作用。在本研究中,旨在获取有关开发有效的基于抗HCV肽疫苗的更多信息,我们检查了人类抗体识别的且目前编入免疫表位数据库(IEDB)的HCV表位与人类蛋白质组的五聚体序列相似性。我们报告称,所分析的HCV决定簇的特征是存在人类蛋白质中不存在(或几乎没有)的片段。这些数据证实了低相似性假说,根据该假说,与宿主蛋白质组的低相似性定义了微生物抗原的非自身特征并调节肽的免疫原性。此外,本研究表明了一种具体且安全的免疫治疗方法,该方法可能用于通用的抗HCV疫苗。